To address the most significant need of treating COVID patients, the India-based subsidiary of  a leading global pharmaceutical company Mylan today has announced a partnership with CSIR. This partnership is directed towards  identifying potential therapies for COVID-19.

As part of this collaboration new and innovative solutions to manage COVID-19 pandemic would be developed and a series of clinical trials would also be conducted. With mild to moderate COVID -19 at risk of complications, the first of the clinical trials to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients .

Director General of CSIR, Dr. Shehkar C Mande stated, “The current collaboration with Mylan is a significant milestone and during the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”

Director of CSIR-IICT, Dr Chandrasekhar said, “CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan’s vast industry experience in clinical trials and commercialization.”

Mylan Chief Operating Officer, Sanjeev Sethi stated, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future.”

Also, as a mentor to lead this collaboration, CSIR has appointed Dr. Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine).